Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)
    HeatherPaque / Pixabay

    The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)

    As many people within the rare disease community know, a rare disease diagnosis can come with a significant financial burden. Additionally, the costs, treatments, equipment, and other needs are not…

    Continue Reading The Assistance Fund Offers New Financial Assistance Program for People with Idiopathic Hypersomnia (IH)
    Orphan Drug Designation Granted to Three Active Moieties of INT230-6 for Soft Tissue Sarcoma (STS)
    Source: Pixabay.com

    Orphan Drug Designation Granted to Three Active Moieties of INT230-6 for Soft Tissue Sarcoma (STS)

    INT230-6, developed by clinical-stage biotechnology company Intensity Therapeutics (“Intensity”), is an investigational therapy comprising three moieties: cisplatin, SHAO-FA (a penetration enhancing molecule), and vinblastine sulfate. A moiety, in this sense,…

    Continue Reading Orphan Drug Designation Granted to Three Active Moieties of INT230-6 for Soft Tissue Sarcoma (STS)

    Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome

    Also known as Richter’s Transformation, Richter syndrome is a rare and aggressive complication of chronic lymphocytic leukemia (CLL). When someone develops Richter syndrome, their CLL can transform into another rare…

    Continue Reading Glofitamab with Obinutuzumab Shows Promise in Heavily Pretreated Richter Syndrome
    Rare Community Profiles: Casting a Light on the Intersection of Mental Health and Chronic Illness: How Elle’s IgAN Journey Inspired Her to Help Others
    https://pixabay.com/en/woman-happiness-sunrise-silhouette-570883/

    Rare Community Profiles: Casting a Light on the Intersection of Mental Health and Chronic Illness: How Elle’s IgAN Journey Inspired Her to Help Others

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: Casting a Light on the Intersection of Mental Health and Chronic Illness: How Elle’s IgAN Journey Inspired Her to Help Others
    Bexmarilimab for AML Granted Orphan Drug Designation
    https://pixabay.com/en/hands-teamwork-team-spirit-cheer-up-1939895/

    Bexmarilimab for AML Granted Orphan Drug Designation

    Currently available therapeutics may not be adequately effective in the fight to treat late-stage acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers and drug developers are working to identify…

    Continue Reading Bexmarilimab for AML Granted Orphan Drug Designation
    Rare Community Profiles: How Madhumita’s Scimitar Syndrome Diagnosis Empowered Her to Understand the Importance of Mental Health
    source: pixabay.com

    Rare Community Profiles: How Madhumita’s Scimitar Syndrome Diagnosis Empowered Her to Understand the Importance of Mental Health

    Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

    Continue Reading Rare Community Profiles: How Madhumita’s Scimitar Syndrome Diagnosis Empowered Her to Understand the Importance of Mental Health
    Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
    kalhh / Pixabay

    Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF

      The U.S. FDA has approved two treatments for people living with idiopathic pulmonary fibrosis (IPF). These therapies—Esbriet (pirfenidone) and Ofev (nintedanib)—both work to reduce fibrosis, or scarring, in the…

    Continue Reading Phase 2b Clinical Study Begins to Evaluate Bexotegrast for IPF
    FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL
    Source: https://pixabay.com/en/white-blood-cell-cell-blood-cell-543471/

    FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL

      In Jordyn Sava's reporting from Targeted Oncology, readers learn that the U.S. Food and Drug Administration (FDA) granted clearance to a global Phase 3 study. This means that the…

    Continue Reading FDA Clears Global Phase 3 Study of Lisaftoclax for Previously Treated CLL or SLL
    China Expands Medical Insurance Coverage to Improve Access and Affordability for Rare Disease Drugs
    Free-Photos / Pixabay

    China Expands Medical Insurance Coverage to Improve Access and Affordability for Rare Disease Drugs

    Unfortunately, gaining access to care within the rare disease space can be difficult. There is often lesser education and awareness about rare conditions, less research performed, and poorer access to…

    Continue Reading China Expands Medical Insurance Coverage to Improve Access and Affordability for Rare Disease Drugs
    Paws for Emma: This Family Needs a Service Dog for Daughter with BRRS
    Source: Pixabay

    Paws for Emma: This Family Needs a Service Dog for Daughter with BRRS

    Soon after Emma Young was born, she was diagnosed with a rare genetic disorder called Bannayan-Riley-Ruvalcaba syndrome (BRRS). At two months old, she battled COVID-19. Then she was diagnosed with…

    Continue Reading Paws for Emma: This Family Needs a Service Dog for Daughter with BRRS
    Study Results Available on Dexpramipexole for Eosinophilic Asthma
    source: shutterstock.com

    Study Results Available on Dexpramipexole for Eosinophilic Asthma

      The Phase 2 EXHALE-1 clinical trial, initiated by clinical-stage biotechnology company Areteia Therapeutics, Inc. ("Areteia"), sought to understand how safe, effective, and well-tolerated dexpramipexole was in reducing symptoms of…

    Continue Reading Study Results Available on Dexpramipexole for Eosinophilic Asthma